Skip to content

Study to evaluate safety and performance of the Evermine 50- 50µm Everolimus Eluting Coronary Stent System (EES) in the treatment of patients with de novo coronary artery lesions

A prospective, post-marketing, multi-center, study to evaluate safety and performance of the Evermine 50- 50µm Everolimus Eluting Coronary Stent System (EES) in the treatment of patients with de novo coronary artery lesions. - Evermine 50 EES – 1

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/02/007781
Enrollment
110
Registered
2017-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

Interventions

Intervention1: Evermine 50 - 50µm Everolimus Eluting Coronary Stent System: Evermine 50 - 50µm Everolimus Eluting Coronary Stent System (EES) in the treatment of patients with de novo coronary artery

Sponsors

Meril Life Sciences Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. The subject must be at least 18 years of age at the time of signing the informed consent. 2. The subject’s legally authorized representative agrees to the subject’s participation in this study and signs the informed consent form. 3. The subject who agree to participate in the study. 4. Only Evermine 50 EES stent(s) is (are) implanted during the index procedure 5. The subject whose coronary artery is suitable for implantation of Evermine 50 EES. 6. Female subject’s of childbearing potential who does not plan pregnancy for up to 2 years from the date of index procedure. For a female subject of childbearing potential a pregnancy test must be performed with negative results at screening visit. 7. Female subject is not breast-feeding at the time of the screening visit and will not be breast-feeding for up to 2 years from the date of index procedure. 8. Subject agrees not to participate in any other investigational or invasive clinical study for a period of 2 years from the date of index procedure

Exclusion criteria

Exclusion criteria: 1. The inability to obtain an informed consent. 2. Subject with known hypersensitivity or allergies to aspirin, heparin, Everolimus, polymer lactide and glycolide antiplatelet drugs (clopidogrel, prasugrel etc). 3. Female subject with known pregnancy or who are lactating at the time of screening

Design outcomes

Primary

MeasureTime frame
Major Adverse Cardiac Events (MACE) Ischemic Driven Target Lesion Revascularization(ID-TLR) Timepoint: [Time Frame: 1 month (±14 days), 6 months (±28days), 12 months (±28 days) and 24 months (±28 days)]

Secondary

MeasureTime frame
Procedural success [Time Frame: Within 24 hours ] Device success Timepoint: Within 24 hours

Countries

India

Contacts

Public ContactDr Ashok Thakkar

Caritas Hospital

drdeepakdavidson@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 5, 2026